Therapeutic drug monitoring for patients with inflammatory bowel disease (IBD) has evolved. In this test-specific episode of the "Answers From the Lab" podcast, Maria Willrich Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' infliximab/adalimumab panel takes a proactive approach.

The test measures both drug concentration and antidrug antibodies in a single panel, to support improved clinical outcomes. "We appreciate that for some patients, proactive monitoring plays a significant role in helping to manage IBD early in the treatment course," Dr. Snyder says.

Clinical decision-making for patients with IBD can be complex. "Our test results will include a panel interpretation with comments to help the provider understand how to best act on the findings related to the antidrug antibody test in the presence of drug," Dr. Willrich says.

Mayo Clinic Laboratories continues to offer reflex testing, a two-step process that measures drug levels and antibodies in response to evidence of active disease. "Having a reflex test and the proactive panel provides versatility for physicians responding to their patients' needs," Dr. Willrich says.

Listen to learn more about Mayo Clinic Laboratories' infliximab/adalimumab panels.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ADALP   | Adalimumab Quantitative with Antibody, Serum

INFXP   | Infliximab Quantitation with Antibodies to Infliximab, Serum

The latest

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D.

May 14, 2024

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

View MoreView Less